What Is My Home Health Agency Worth? How Buyers Value It
A plain-English valuation guide for owners of $5M–$200M home health agencies — what a buyer actually pays, and the levers that move your multiple by one to four full turns depending on Medicare certification, payor mix, and star rating.
Updated 2026-06-12·Updated 2026 · 12 min read·Healthcare Services & IT
Typical multiple
3x – 12x
Priced on Adjusted EBITDA · Typical 7.5x
Triangulated from Scope Research's Healthcare M&A Valuation Database (138 home-health deals), Mertz Taggart Q1 2026 home-based-care M&A report, Breakwater M&A 2026, and named PE/strategic deals Q4 2025–Q2 2026
- Adjusted EBITDA multiple range
- 3x – 12x
- LMM midpoint (certified)
- 7.5x
- Medicare certification premium
- 1.5x – 2x
- Basis pivot at ~$2M value
- SDE → EBITDA
The short answer
A home health agency is worth a multiple of its normalized earnings — but the band you land in depends almost entirely on one binary fact: Medicare certification. In 2026, non-medical private-duty agencies trade at 3x–5x adjusted EBITDA, Medicare-certified regional agencies at 6x–9x, and scaled multi-state platforms at 9x–12x+.[1][2] The overall range is 3x–12x with a midpoint around 7.5x for solid certified agencies.[1]
Estimate vs. reality
A calculator estimate is not what a buyer pays
Type your revenue or EBITDA into a free calculator and you get a generic healthcare multiple. That is a starting point, not a price. A buyer pays for certified, normalized earnings benchmarked against real home health comps — and in no LMM sector does that gap move value as dramatically as in home health, where segment and certification status alone can shift the multiple by 4–7 full turns.[3][4]
- Revenue or EBITDA × a single generic healthcare multiple
- No distinction between non-certified personal care and Medicare-certified skilled home health
- No adjustment for payor mix, CMS star rating, or referral-source concentration
- Stale or public-company multiples not adjusted for private illiquidity or PDGM reimbursement risk
- Adjusted EBITDA validated in diligence, with ADR reserves and owner-compensation add-backs documented
- A multiple gated first by Medicare certification status, then by payor mix and CMS star rating
- Referral-source diversification — no single hospital or SNF above 50% of census
- Licensure transferability — CHOW timeline, Medicare re-enrollment, and accreditation status
- A structured price including rollover equity, earn-out tied to post-close star-rating maintenance, and ADR reserve escrow
In owner-operated home health agencies, a non-certified agency and a Medicare-certified agency at identical revenue and EBITDA can differ by 2x–3x in enterprise value — the certification gate is binary and no amount of EBITDA normalization closes it.[1][2]
Earnings basis
SDE or EBITDA? It depends on your size
The most consequential framing question for home health owners is which earnings metric applies — and which segment you operate in determines both the metric and the buyer pool.
| Business size | Priced on | Typical multiple | What's going on |
|---|---|---|---|
| Under ~$2M value (owner-run) | SDE | 2.1x – 4.0x SDE (median ~3x) | Owner-dependent single-branch; non-certified personal care typical; individual or small-strategic buyers; referral concentration and owner-administrator dual role cap the multiple.[1] |
| $2M – $10M EV (certified regional) | Adjusted EBITDA | 3x – 6x | Single-branch to small multi-branch; Medicare-certified skilled home health; PE-backed roll-ups (Pennant, BrightSpring, Addus) enter this band; payor diversification and star rating drive position within range.[1][2] |
| $10M – $50M EV (multi-branch platform add-on) | Adjusted EBITDA | 6x – 8x (hospice to 10x+) | Multi-branch; payer diversification, 4.5–5 star ratings rewarded; hospice mix commands the top of the band; PE platforms require mandatory rollover equity.[2][3] |
| $50M+ EV (multi-state platform) | Adjusted EBITDA | 7x – 12x+ | Multi-state certified platforms with health-system relationships; 2026 anchor Kinderhook/Enhabit at ~10.7x on $103.1M TTM Adjusted EBITDA across 34 states.[6][7] |
Per the IBBA/M&A Source Market Pulse framing, businesses valued under ~$2M are priced on SDE (which adds back the owner's full compensation); those at $2M and above are priced on adjusted EBITDA (which subtracts a market-rate replacement manager). For home health, this pivot matters doubly: a single-branch owner-run agency where the owner serves as administrator and DON is a SDE-basis business; a multi-branch certified agency with professional management is an EBITDA-basis business.[5][5]
Interactive estimate
Estimate what your home health agency is worth
Move the sliders. The range reflects how each driver pushes the multiple up or down for a home health agency. Treat it as a planning anchor — not a formal valuation.
The single most important fact in home health valuation. Medicare-certified agencies command a 1.5–2x higher multiple than non-certified peers. Non-certified personal-care agencies cap at 3–5x; certified skilled clears 5–8x at the same revenue scale.
The #1 internal value driver an owner controls. A diversified book (e.g., 40% Medicare / 30% Medicaid / 30% private/MA) lifts the multiple +1–2 turns. Single managed-care contract concentration above 80% is a severe drag.
4.5–5 star agencies earn approximately a +1.5x multiple premium because high ratings proxy for clinical compliance quality. Open ADRs, RAC audit findings, or CMS survey deficiencies push the multiple to the lower end of the band.
Heavy dependence on a single hospital discharge planner, SNF, or MSO for census is a severe drag; buyers price this risk through earnout holdbacks or decline to transact. Diversified referrals across 5+ sources add stability premium.
Estimated enterprise value
$6.0M – $9.6M
Implied multiple: 5.0x – 8.0x Adjusted EBITDA
Illustrative planning range only, based on typical home health multiples and driver sensitivities — not a formal valuation or an offer.
Methodology
The three ways a home health agency gets valued
A credible valuation triangulates across all three. Any single number in isolation is suspect.
Market approach — comparable home health transactions
Default for certified agencies with stable censusThe market approach values your agency against actual sale prices and multiples of comparable home health companies. It dominates because home health has an unusually data-rich comparable-transaction population relative to other LMM service verticals — Scope Research's Healthcare M&A Valuation Database holds 138 home-health deals with 94 reported EBITDA multiples, and Mertz Taggart publishes quarterly home-based-care M&A reports.[1][2] Buyers and advisors build the comp set on three axes: certification status (Medicare-certified vs. non-medical is the binary gate separating two distinct buyer pools and two distinct multiple bands), sub-segment (skilled home health vs. hospice vs. personal care), and scale (single-branch regional vs. multi-state platform).[1]
A 2026 public anchor grounds the top of the range: Kinderhook Industries agreed to acquire Enhabit Inc. (NYSE: EHAB) at ~$1.1B TEV implying ~10.7x on $103.1M TTM Adjusted EBITDA, covering 249 home-health and 117 hospice locations across 34 states.[6][7]
Income approach — DCF with payor-mix and regulatory forecast
Cross-check for certified agencies with forecastable censusStandard discounted cash flow is a secondary cross-check for home health because reimbursement is administratively set, not market-priced. A credible forecast requires explicit modeling of Medicare PDGM-adjusted episode revenue (including the ~1.3% CY2026 rate reduction), Medicaid revenue by state rate trajectory, Medicare Advantage commercial-rate trends, and caregiver cost inflation.[2][3] The income approach carries the most weight for large multi-state certified platforms where PDGM performance scores and payor contracts are stable and auditable; for a single-branch owner-run agency, multi-year projections are difficult to defend.
One trap to avoid: modeling forward census growth without stress-testing the Change of Ownership (CHOW) re-enrollment scenario — a 90–180 day enrollment gap during ownership transfer can produce a real revenue interruption that a naive DCF model misses entirely.[2]
Asset approach — adjusted net assets and Medicare provider number
Floor check; provider number carries standalone valueFor a healthy home health agency, asset value (working capital, accounts receivable aged by payor, leasehold improvements, EHR, and accreditation) lands well below operating value — it sets a floor, not the price. Its primary use is a sanity check: if asset value is within 30% of operating value, EBITDA quality may be overstated or ADR exposure understated.[4]
One asset deserves unique attention: the Medicare provider number itself. It is the regulatory key that gates the entire valuation tier — a non-certified agency looking to acquire one faces a 6–24 month new-enrollment timeline with no revenue guarantee, and buyers priced this scarcity directly into the Kinderhook/Enhabit transaction.[6][7] In CON states (Florida, Georgia, North Carolina, Kentucky, Ohio), the Certificate of Need is a separately valued, transferable asset that creates an additional structural barrier to competitive entry.[1]
Value drivers
What moves the multiple for a home health agency
Medicare certification (binary gate)
+1.5x – 2x multipleMedicare certification is the highest-weighted variable in home health valuation. Certified agencies command a 1.5–2x higher multiple than non-certified peers — a non-medical agency at $4M revenue clearing $400K EBITDA might achieve $1.2M–$2M enterprise value (3–5x), while a Medicare-certified agency at the same scale commands $2M–$3.2M (5–8x).[2] Certification creates regulatory barriers to entry: a buyer cannot simply replicate a Medicare provider number in a new market, making the certified footprint uniquely valuable.[1] Non-certification is the one driver that cannot be improved incrementally — it is binary, and the gap it creates cannot be closed by EBITDA normalization alone.
Diversified payor mix (Medicare / Medicaid / private / MA)
+1x – 2x turnsPayor mix is the #1 internal value driver a home health owner controls. A diversified book — for example, approximately 40% Medicare / 30% Medicaid / 30% private or Medicare Advantage — lifts the multiple +1–2 turns versus a concentrated mix.[2] The sector-wide headwind of a ~1.3% CY2026 Medicare payment reduction compounds reimbursement risk for Medicaid-heavy agencies, further widening the spread between diversified and concentrated payors.[2][3] Buyers model payor-mix stress scenarios in diligence, and concentrated single-managed-care-contract books above 80% frequently trigger earnout holdbacks.
CMS 4.5–5 star rating
+1.5x premium (approx.)A 4.5–5 CMS star rating earns approximately a +1.5x multiple premium because it functions as a fast-screen proxy for clinical compliance quality — it signals to PE and strategic underwriters that post-close regulatory exposure is low.[3] Open Additional Documentation Requests (ADRs), Recovery Audit Contractor (RAC) audit findings, or recent CMS survey deficiencies push an agency to the lower end of its applicable band regardless of EBITDA quality, and often create an escrow reserve obligation at close that effectively reduces net proceeds.
Caregiver retention below 40% turnover
+0.5x – 1.0xIndustry caregiver turnover averages approximately 79.4% per Activated Insights 2024 data — agencies holding sub-40% turnover significantly de-risk post-close operations and command a premium.[2] A tenured Director of Nursing (DON) and Administrator who commit to staying through close adds a demonstrable transition premium, typically modeled as +$25K–$150K to enterprise value, because it eliminates the most common integration-risk flag buyers raise in clinical due diligence.[3]
Non-certified / non-medical status
Caps multiple at 3x – 5xNon-certified agencies cannot cross into the 5–8x Medicare-certified band regardless of EBITDA quality or operational excellence.[1][2] The buyer pool shrinks to individual operators and small strategic roll-ups, and the deal is typically valued on SDE at smaller scale. This is the most consequential downward driver — unlike star rating or payor mix, non-certification cannot be improved incrementally before a sale.
Payor or referral concentration above 80%
−1x – 2x or deal-killerA single managed-care contract representing more than 80% of revenue, or a single referral source (a particular hospital discharge planner, SNF, or MSO) generating a disproportionate share of census, is the highest-severity drag in home health deal structures.[2] Buyers price this risk through earnout holdbacks tied to payor and referral retention, or decline to transact entirely. The combination of referral concentration with an exiting owner-administrator — the two most common drag factors — can reduce proceeds by 30–50% versus a clean comparable agency at the same EBITDA.[3]
Owner-administrator / clinical dependency
−1x – 2x; forces SDE basisAn owner-administrator handling the DON or clinical leadership role means the agency cannot pass a CMS survey or sustain census without owner involvement — triggering a shift from EBITDA-multiple valuation to SDE-multiple valuation at smaller scale.[2] Buyers normalize to a market replacement salary for a DON plus Administrator ($120K–$200K combined depending on state) and rebuild EBITDA from there. Single-branch agencies with this profile land at the 3–5x band floor, often with a 12–24 month earnout requiring the exiting owner to support the ownership transition.[3]
High ADR exposure / open audit findings
−0.5x – 1.5x; triggers escrow reserveOpen ADRs, RAC audit findings, or one-time CMS settlements must be normalized out of base-year EBITDA — and a separate escrow reserve is held at close against forward audit risk, typically 5–10% of enterprise value.[2][3] This is the most home-health-specific valuation adjustment; buyers who encounter undisclosed audit exposure mid-diligence routinely re-trade on price or restructure to a heavier earnout. Quantifying and disclosing all audit exposure before the process begins is essential to controlling the narrative.
Worked example
A $10M-revenue Medicare-certified agency, step by step
An illustrative Medicare-certified skilled home health agency with two branches, diversified payor mix (approximately 40% Medicare / 35% Medicaid / 25% private pay), a stable DON and Administrator, and a 4.5 CMS star rating. Numbers are illustrative, not a specific company.
Annual revenue
$10.0M
Medicare-certified skilled home health; two-branch regional
Adjusted EBITDA
$1.2M
≈12% margin after owner add-backs and ADR normalization[4]
Applied multiple
6.0x
Certified; diversified payor mix; 4.5-star; mid-range add-on[1][2]
Enterprise value
≈ $7.2M
Adjusted EBITDA × multiple
Indicative result
≈ $7.2M enterprise value
A non-certified variant at the same revenue tells the other half of the story: a non-medical personal-care agency with $10M revenue at an 8% EBITDA margin is $800K EBITDA × 4.0x ≈ $3.2M — certification and margin together more than double the value at identical revenue.[1][2] This is illustrative, not an offer or a formal valuation.
Cost & who does it
What a home health agency valuation costs — and who should do it
Before anchoring on any number, get your normalized earnings right — and in home health, that means ADR-adjusted EBITDA with documented owner add-backs and a defensible payor-mix summary. The right tool depends on why you need the valuation.
Broker / advisor opinion of value
Free – $5,000
Best for
Testing the market, setting a listing range
Fast; not certified; not accepted by the IRS or courts. Many M&A advisors provide a preliminary home health estimate at no cost to win an engagement.
Formal certified appraisal (USPAP)
$5,000 – $30,000+
Best for
Estate or gift tax, ESOP, litigation, partner buyout, SBA
Performed by a credentialed appraiser (CVA / ABV / ASA); defensible to the IRS and courts. Required for any regulatory or legal trigger.
Quality of earnings (QoE)
$15,000 – $75,000+
Best for
Validating adjusted EBITDA and ADR exposure before going to market
Not an audit; tests add-backs, working capital, and open audit reserves — often pays for itself in re-trade protection. Standard practice for home health deals above $5M revenue.
For most $5M–$200M home health owners the sequence is: an advisor opinion of value to orient, a sell-side QoE to prepare and defend your adjusted EBITDA (and surface ADR exposure before a buyer does), and a certified appraisal only if a tax, legal, or ESOP trigger requires it. Home health deals above $10M revenue almost universally require a sell-side QoE because buyers will commission their own — and a documented add-back schedule dramatically reduces the risk of mid-diligence re-trades.[4][8] With Ad Astra's verified $1B+ in closed transaction value, a confidential opinion of value is a no-obligation place to start — book a confidential call.
Before you sell
How to increase your valuation before going to market
The gap between a 3x non-certified agency and a 9x+ certified platform is built over 12–36 months, not negotiated at the table. These levers are the focus of our value enhancement work for home health owners who have 1–3 years of runway before going to market.
Diversify payor mix away from single-payer concentration
+1x – 2x turnsIf more than 60–70% of your revenue flows through a single Medicaid managed-care organization or a single Medicare Advantage plan, you are leaving 1–2 turns on the table that diversification can recover. Systematic outreach to physician offices, SNF discharge planners, and community-based organizations — and building new referral relationships over 12–18 months — shifts the buyer's risk calculus materially.[2] Even moving from 80% single-payer to 60% shifts you from an earnout-heavy structure to a cleaner cash-at-close deal.
Improve CMS star rating and eliminate open audit findings
+1x – 1.5xSystematically improving OASIS-E accuracy and HHVBP functional outcome scores over 12–18 months is the most direct path to the 4.5–5 star premium.[3] Simultaneously, proactively resolving open ADRs and RAC audit findings before entering the sale process eliminates the escrow reserve that otherwise reduces net proceeds — a reserve that buyers typically set at 5–10% of enterprise value.[2][3] Combined, these actions can be worth more than a full turn of EBITDA multiple.
Install professional management and reduce owner-clinical dependency
+1x – 2x turnsA tenured Director of Nursing and Administrator who can pass a CMS survey and sustain census without the owner's involvement is the prerequisite for crossing from the 3–5x owner-dependent band into the 6–9x professional-management band.[2][3] If the owner currently doubles as administrator or clinical coordinator, hiring and training replacements 18–24 months before a sale allows the business to demonstrate post-owner performance — the single most important transition story a buyer needs to underwrite a premium multiple.
Add hospice or Medicaid-waiver lines for stickier, higher-multiple revenue
+0.5x – 2x on blended multipleHospice is the "crown jewel" of the home health category — it trades at 9x–12.5x EBITDA as a standalone, and blending even a modest hospice or Medicaid-waiver program into a certified home health platform lifts the blended multiple and broadens the buyer pool to include hospice-focused PE platforms.[1][2] Adding hospice accreditation requires 12–18 months of planning but the multiple lift is among the largest available to a home health owner.
FAQ
Common questions about home health agency valuation
Go deeper on home health agency multiples
Value another business
From estimate to real number
Get an owner-grade valuation of your home health agency
A confidential 30-minute call with Clayton or Joe gives you a real range, the adjustments we'd apply to your reported earnings, and the one or two moves that close the gap fastest — built on healthcare services & it deal data.
- [1] Scope Research — Home Health Valuation Multiples and M&A Trends 2025
- [2] Breakwater M&A — Home Care Agency Valuation Multiples 2026
- [3] Home Care Business Broker — 2026 Healthcare Home Care Valuation Multiples
- [4] Exitwise — How Much is a Home Health Agency Worth
- [5] Morgan & Westfield — Should I Use SDE or EBITDA to Value a Business?
- [6] Mertz Taggart — Q1 2026 Home-Based Care M&A Report
- [7] Enhabit Inc. (NYSE: EHAB) Q2 2025 8-K — $103.1M TTM Adj. EBITDA; 249 home-health + 117 hospice locations across 34 states
- [8] CT Acquisitions — Prepare Your Home Health Agency for Sale 2026
Ranges represent typical lower middle market transactions; individual deals may fall outside the band based on buyer thesis, deal structure, and company-specific factors. This page is informational and not a formal valuation opinion.